Log In
BCIQ
Print this Print this
 

Low dose IL-6, atexakin alfa

  Manage Alerts
Collapse Summary General Information
Company Merck KGaA
DescriptionRecombinant human IL-6
Molecular Target Interleukin-6 (IL-6) receptor (CD126)
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard IndicationNeuropathy
Indication DetailsTreat diabetic neuropathy; Treat neuropathy
Regulatory Designation
PartnerRelief Therapeutics Holding AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/07/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today